ImmunoVaccine Technologies Licenses Immunotope's Breast, Ovarian and Prostate Cancer Antigens
Posted on: Tuesday, 14 July 2009, 08:00 CDT
"Advanced-stage breast, ovarian and prostate cancers remain devastating and challenging diseases that urgently need treatment options, and we are excited to use Immunotope's antigens in our platform" said Dr.
"This agreement combines our antigen discovery expertise with IVT's product development capabilities and we are pleased to have our antigens become part of such an innovative vaccine candidate," said
Under the license agreement, IVT has agreed to an up-front payment, as well as future milestone payments and royalties to Immunotope for use of the antigens. This licensing agreement replaces the acquisition of Immunotope agreement.
DPX-0907 is a novel vaccine because of its potential to create a depot at the injection site and cause a strong, rapid, long-lasting immune response that specifically targets cancer cells.
ImmunoVaccine Technologies is strengthening its innovative vaccine pipeline through licensing and strategic partnering to develop therapeutic cancer and infection disease vaccines. In 2008, Pfizer Animal Health licensed its proprietary DepoVax(TM) technology for two livestock vaccines. With positive pre-clinical safety data and recent partnerships with LIAI, NIH, Yokohoma City University, Defence Research Development Canada and FIT Biotech, the value of Depovax(TM) has been brought into the limelight. www.immunovaccine.com.
This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future are forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. IVT assumes no responsibility to update forward-looking statements in this press release.
SOURCE ImmunoVaccine Technologies Inc.
Source: PR Newswire
Related Articles
- Swine Flu Vaccine Moves Into Clinical Testing
- GSK Cervical Cancer Candidate Vaccine CERVARIX (R) Demonstrates Long-Term Protection for More Than Six Years
- First Prostate Cancer Patients Treated in a Phase I Clinical Trial As Part of a Collaboration Between Generex Biotechnology and the Saint Savas Cancer Hospital
- GSK's Cervical Cancer Candidate Vaccine Cervarix(TM) Receives Positive Opinion in Europe for Prevention of Cervical Cancer
- Bio-Bridge Science Completes Major Construction of Facility to Produce Vaccines and Support Clinical Activities
- Bernanke Says Fed Policy Must Be Forward-looking
- Westinghouse Lauds Progress Energy for Proactive, Forward-Looking Approach to Nuclear Fleet Expansion
- First Patient Enrolled in Investigator-Sponsored Phase 1/2 Trial of Antigenics' Oncophage Cancer Vaccine in Glioma
- China's Self-Made Human Avian Influenza Vaccine Ready for Clinical Test
- Chinese Anti-Cancer Vaccine Approved for Clinical Research
 |
 |
User Comments (0)
RSS Feeds